TAVR vs Surgical AVR: Which for Patients Under 65?

For patients under 65 with severe aortic stenosis, current guidelines recommend surgical aortic valve replacement as the preferred option. US and international cardiology guidelines support SAVR as the first-choice procedure in this age group, with TAVR considered only when surgical risk is elevated or the patient declines open surgery. A 55-year-old getting a bioprosthetic TAVR valve today will likely outlive that valve and face a redo procedure. SAVR with a mechanical valve or surgical bioprosthesis consistently outperforms TAVR on long-term durability in this age group.

According to Dr. Vishal Khullar, a leading Cardiac Surgeon in Mumbai, “TAVR changed what’s possible for elderly high-risk patients. But under 65, the conversation shifts. These patients have decades ahead of them, and the valve has to last. That’s where surgical AVR still holds the stronger hand.”

Two procedures. Same indication, different long-term trajectories. Here is the comparison for under-65 patients.

Valve longevity: SAVR with a mechanical valve carries no structural deterioration risk. Lifelong warfarin is the trade-off. Surgical bioprostheses last 15 to 20 years. TAVR bioprostheses show higher structural valve deterioration at 10 years in younger patients.

Reoperation risk: Redo TAVR or surgical conversion after TAVR failure carries higher mortality than primary SAVR. Mechanical SAVR avoids this trajectory entirely. That risk calculus changes considerably when the patient is 55 rather than 80.

Pacemaker implantation: TAVR carries a permanent pacemaker rate of 10 to 20 percent depending on the device. Surgical AVR rates are substantially lower. In a younger patient that represents decades of pacemaker management and device replacement.

Recovery: TAVR patients go home in two to three days. SAVR requires five to seven days and six to eight weeks of full recovery. For a working-age patient that gap factors into shared decision-making even when SAVR is the stronger clinical choice.

For a broader look at how TAVR compares to open surgery in higher-risk patients, read our blog on aortic valve replacement.

Dr. Vishal Khullar is the Director of Cardiovascular and Thoracic Surgery, Heart and Lung Transplant at Fortis Hospital Mulund and Fortis S.L. Raheja Hospital, Mumbai. Over 30 years in the field. Training at Cleveland Clinic and Mayo Clinic in the USA. More than 7,000 completed procedures, including extensive experience in both TAVR and open aortic valve replacement across all risk profiles.

His valve assessments are anatomy-driven and age-specific. Younger patients get a direct, evidence-based answer on which approach protects their long-term interests, not just their short-term recovery. Call +91 99870 77880 to book your consultation.

1. PMC (NIH) – TAVR vs SAVR in Patients Aged 50 to 64 in the United States 
2. PMC (NIH) – Real-World Comparison of TAVR vs SAVR Outcomes